Interethnic Differences in Pharmacokinetics of Antibacterials

Clinical Pharmacokinetics

Volumn 54, Issue 3, 2015, Pages 243-260

  Tsai, Danny ^a,b   Jamal, Janattul Ain ^a   Davis, Joshua S ^c   Lipman, Jeffrey ^a,d   Roberts, Jason A ^a,d,e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ALICE SPRINGS HOSPITAL   (Australia)

^c MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^d ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; DAPTOMYCIN; GLYCOPEPTIDE; LINCOSAMIDE; LINEZOLID; MACROLIDE; NITROIMIDAZOLE DERIVATIVE; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLONE DERIVATIVE; TINIDAZOLE;

ACTIVE TRANSPORT; ASIAN; BODY FAT DISTRIBUTION; BODY SIZE; CAUCASIAN; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG TRANSPORT; ENVIRONMENTAL FACTOR; ETHNIC DIFFERENCE; HUMAN; INFORMATION RETRIEVAL; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; URINARY EXCRETION; ADIPOSE TISSUE; ETHNIC GROUP; METABOLISM;

ADIPOSE TISSUE; ANTI-BACTERIAL AGENTS; ETHNIC GROUPS; HUMANS;

EID: 84925500513     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-014-0209-3     Document Type: Review

References (223)

1. Zhou HH, Adedoyin A, Wilkinson GR. Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther. 1990;48(1):10–7.
2. Tornatore KM, Sudchada P, Dole K, DiFrancesco R, Leca N, Gundroo AC, et al. Mycophenolic acid pharmacokinetics during maintenance immunosuppression in African American and Caucasian renal transplant recipients. J Clin Pharmacol. 2011;51(8):1213–22.
3. Palma-Aguirre JA, Gonzalez-Llaven J, Flores-Murrieta FJ, Castaneda-Hernandez G. Bioavailability of oral cyclosporine in healthy Mexican volunteers: evidence for interethnic variability. J Clin Pharmacol. 1997;37(7):630–4.
4. Kalow W. Ethnic differences in drug metabolism. Clin Pharmacokinet. 1982;7(5):373–400.
5. Ortolani O, Conti A, Ngumi ZW, Texeira L, Olang P, Amani I, et al. Ethnic differences in propofol and fentanyl response: a comparison among Caucasians, Kenyan Africans and Brazilians. Eur J Anaesthesiol. 2004;21(4):314–9.
6. Johnson JA. Influence of race or ethnicity on pharmacokinetics of drugs. J Pharm Sci. 1997;86(12):1328–33.
7. Chun TY, Bankir L, Eckert GJ, Bichet DG, Saha C, Zaidi SA, et al. Ethnic differences in renal responses to furosemide. Hypertension. 2008;52(2):241–8.
8. Ahsan CH, Renwick AG, Macklin B, Challenor VF, Waller DG, George CF. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol. 1991;31(4):399–403.
9. Povoa P. Serum markers in community-acquired pneumonia and ventilator-associated pneumonia. Curr Opin Infect Dis. 2008;21(2):157–62.
10. Wood AJ, Zhou HH. Ethnic differences in drug disposition and responsiveness. Clin Pharmacokinet. 1991;20(5):350–73.
11. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001;41:815–50.
12. Johnson JA. Predictability of the effects of race or ethnicity on pharmacokinetics of drugs. Int J Clin Pharmacol Ther. 2000;38(2):53–60.
13. Kim K, Johnson JA, Derendorf H. Differences in drug pharmacokinetics between East Asians and Caucasians and the role of genetic polymorphisms. J Clin Pharmacol. 2004;44(10):1083–105.
14. Hosseine SJ, Farid R, Ghalighi MR, Feely J. Interethnic differences in drug protein binding and alpha 1 acid glycoprotein concentration. Ir J Med Sci. 1995;164(1):26–7.
15. Daly AK. Significance of the minor cytochrome P450 3A isoforms. Clin Pharmacokinet. 2006;45(1):13–31.
16. Saag M, Balu R, Phillips E, Brachman P, Martorell C, Burman W, et al. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin Infect Dis. 2008;46(7):1111–8.
17. Liu R, Tang AM, Tan YL, Limenta LM, Lee EJ. Interethnic differences of PEPT2 (SLC15A2) polymorphism distribution and associations with cephalexin pharmacokinetics in healthy Asian subjects. Eur J Clin Pharmacol. 2009;65(1):65–70.
18. Yu KS, Cho JY, Shon JH, Bae KS, Yi SY, Lim HS, et al. Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin. Clin Pharmacol Ther. 2001;70(3):228–36.
19. Chang XY, Guo T, Xia DY. Pharmacokinetics of tinidazole in Chinese subjects: comparison of Mongolian, Korean, Hui, Uighur and Han nationalities. J Pharm Pharm Sci. 2009;12(2):175–80.
20. Jhee SS, Burm JP, Gill MA. Comparison of aminoglycoside pharmacokinetics in Asian, Hispanic, and Caucasian patients by using population pharmacokinetic methods. Antimicrob Agents Chemother. 1994;38(9):2073–7.
21. Nandy P, Samtani MN, Lin R. Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients. Antimicrob Agents Chemother. 2010;54(6):2354–9.
22. Meagher AK, Ambrose PG, Grasela TH, Ellis-Grosse EJ. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005;41(Suppl 5):S333–40.
23. McAndrews KI, Murphy JE. Aminoglycoside pharmacokinetics in Alaskan natives. Am J Health Syst Pharm. 1995;52:2015–8.
24. Zaske DE, Cipolle RJ, Rotschafer JC, Solem LD, Mosier NR, Strate RG. Gentamicin pharmacokinetics in 1,640 patients: method for control of serum concentrations. Antimicrob Agents Chemother. 1982;21(3):407–11.
25. Xiao YH, Gao L, Li Y, Lu Y, Liu J, Liu Y. Comparison of pharmacokinetics/pharmacodynamics of cefdinir, cefpodoxime proxetil and cefaclor against common bacteria of community acquired infections. Zhonghua Yi Xue Za Zhi. 2004;84(22):1867–71.
26. Chen J, Jiang B, Lou H, Yu L, Ruan Z. Bioequivalence evaluation of cefdinir in healthy fasting subjects. Arzneimittelforschung. 2012;62(1):9–13.
27. Chen ZJ, Zhang J, Yu JC, Cao GY, Wu XJ, Shi YG. Selective method for the determination of cefdinir in human plasma using liquid chromatography electrospray ionization tandem mass spectrometry. J Chromatogr B Anal Technol Biomed Life Sci. 2006;834(1–2):163–9.
28. Richer M, Allard S, Manseau L, Vallee F, Pak R, LeBel M. Suction-induced blister fluid penetration of cefdinir in healthy volunteers following ascending oral doses. Antimicrob Agents Chemother. 1995;39(5):1082–6.
29. Shoaib MH, Shaikh D, Yousuf RI, Naqvi BS, Hashmi K. Pharmacokinetic study of cephradine in Pakistani healthy male volunteers. Pak J Pharm Sci. 2008;21(4):400–6.
30. Rattie ES, Bernardo PD, Ravin JJ. Pharmacokinetic interpretation of cephradine levels in serum after intravenous and extravascular administration in humans. Antimicrob Agents Chemother. 1976;10(2):283–7.
31. Kang YS, Lee SY, Kim NH, Choi HM, Park JS, Kim W, et al. A specific and rapid HPLC assay for the determination of cefroxadine in human plasma and its application to pharmacokinetic study in Korean. J Pharm Biomed Anal. 2006;40(2):369–74.
32. Ohkawa M, Takamae K, Shimamura M, Kuroda K, Awazu S. Pharmacokinetics of cefroxadine in healthy volunteers and patients with impaired renal function. Chemotherapy. 1981;27(3):149–54.
33. Bergan T. Pharmacokinetics of a new cephalosporin, CGP 9000 (cefroxadine), in healthy volunteers. Chemotherapy. 1980;26(4):225–30.
34. Gerardin A, Lecaillon JB, Schoeller JP, Humbert G, Guibert J. Pharmacokinetics of cefroxadin (CGP 9000) in man. J Pharmacokinet Biopharm. 1982;10(1):15–26.
35. Liang D, Qin Y, Xu N, Zhang H, Li J. Pharmacokinetics of ciprofloxacin in young healthy volunteers [in Chinese]. Hua Xi Yi Ke Da Xue Xue Bao. 1993;24(3):306–8.
36. Harahap Y, Prasaja B, Indriati E, Lusthom W, Lipin. Bioequivalence of ciprofloxacin tablet formulations assessed in Indonesian volunteers. Int J Clin Pharmacol Ther. 2007;45(6):373–6.
37. Sudo RT, Melo PA, Suarez-Kurtz G. Pharmacokinetics of oral ciprofloxacin in healthy, young Brazilian subjects. Braz J Med Biol Res. 1990;23(12):1315–21.
38. Bender SW, Dalhoff A, Shah PM, Strehl R, Posselt HG. Ciprofloxacin pharmacokinetics in patients with cystic fibrosis. Infection. 1986;14(1):17–21.
39. Borner K, Hoffken G, Lode H, Koeppe P, Prinzing C, Glatzel P, et al. Pharmacokinetics of ciprofloxacin in healthy volunteers after oral and intravenous administration. Eur J Clin Microbiol. 1986;5(2):179–86.
40. Brittain DC, Scully BE, McElrath MJ, Steinman R, Labthavikul P, Neu HC. The pharmacokinetics and serum and urine bactericidal activity of ciprofloxacin. J Clin Pharmacol. 1985;25(2):82–8.
41. Chukwuani CM, Coker HA, Oduola AM, Ifudu ND, Sowunmi A. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers. Chemotherapy. 1998;44(6):369–76.
42. Hong Z, Wang Y, Xu N, Zhang H, Liang D. Pharmacokinetics of ciprofloxacin injection in healthy volunteers [in Chinese]. Hua Xi Yi Ke Da Xue Xue Bao. 1995;26(3):315–8.
43. Al-Talla ZA, Akrawi SH, Emwas AH. Solid state NMR and bioequivalence comparison of the pharmacokinetic parameters of two formulations of clindamycin. Int J Clin Pharmacol Ther. 2011;49(7):469–76.
44. Li J, Wang N, Zhang ZJ, Tian Y, Tang W, Chen Y. Pharmacokinetics and bioequivalence study of clindamycin hydrochloride formulations after single-dose administration in healthy Chinese male volunteers. Arzneimittelforschung. 2008;58(7):358–62.
45. Sanki UK, Mandal BK, Chandrakala V. Comparative pharmacokinetics study of two different clindamycin capsule formulations: a randomized, two-period, two-sequence, two-way crossover clinical trial in healthy volunteers. Arzneimittelforschung. 2011;61(9):538–43.
46. Cho SH, Im HT, Park WS, Ha YH, Choi YW, Lee KT. Simple method for the assay of clindamycin in human plasma by reversed-phase high-performance liquid chromatography with UV detector. Biomed Chromatogr. 2005;19(10):783–7.
47. Gatti G, Flaherty J, Bubp J, White J, Borin M, Gambertoglio J. Comparative study of bioavailabilities and pharmacokinetics of clindamycin in healthy volunteers and patients with AIDS. Antimicrob Agents Chemother. 1993;37(5):1137–43.
48. Mazur D, Schug BS, Evers G, Larsimont V, Fieger-Buschges H, Gimbel W, et al. Bioavailability and selected pharmacokinetic parameters of clindamycin hydrochloride after administration of a new 600 mg tablet formulation. Int J Clin Pharmacol Ther. 1999;37(8):386–92.
49. Boonleang J, Panrat K, Tantana C, Krittathanmakul S, Jintapakorn W. Bioavailability and pharmacokinetic comparison between generic and branded azithromycin capsule: a randomized, double-blind, 2-way crossover in healthy male Thai volunteers. Clin Ther. 2007;29(4):703–10.
50. Najib NM, Idkaidek N, Ghanem IE, Admour I, Mahmood Alam S, Zaman Q, et al. Bioequivalence assessment of Azomycin (Julphar, UAE) as compared to Zithromax (Pfizer, USA)—two brands of azithromycin—in healthy human volunteers. Biopharm Drug Dispos. 2001;22(1):15–21.
51. Pineyro-Lopez A, Pineyro-Garza E, Torres-Alanis O, Reyes-Araiza R, Gomez Silva M, Wacksman N, et al. Bioavailability of two oral formulations of azithromycin 500 mg: a randomized, open-label, two-period crossover comparison in healthy Mexican adult subjects. Clin Ther. 2005;27(10):1607–11.
52. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother. 1990;25(Suppl A):73–82.
53. Chen L, Qin F, Ma Y, Li F. Quantitative determination of azithromycin in human plasma by ultra performance liquid chromatography–electrospray ionization mass spectrometry and its application in a pharmacokinetic study. J Chromatogr B Anal Technol Biomed Life Sci. 2007;855(2):255–61.
54. Xue-Min Z, Jie L, Juan G, Quan-Sheng Y, Wen-Yan W. Determination of azithromycin in human plasma by LC–MS–MS and its pharmacokinetics. Pharmazie. 2007;62(4):255–7.
55. Birkett DJ, Robson RA, Grgurinovich N, Tonkin A. Single oral dose pharmacokinetics of erythromycin and roxithromycin and the effects of chronic dosing. Ther Drug Monit. 1990;12(1):65–71.
56. Hovi T, Josefsson K, Renkonen OV. Erythromycin absorption in healthy volunteers from single and multiple doses of enteric-coated pellets and tablets. Eur J Clin Pharmacol. 1983;25(2):271–3.
57. Chu SY, Sennello LT, Bunnell ST, Varga LL, Wilson DS, Sonders RC. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral doses. Antimicrob Agents Chemother. 1992;36(11):2447–53.
58. Amini H, Ahmadiani A. Sensitive determination of clarithromycin in human plasma by high-performance liquid chromatography with spectrophotometric detection. J Chromatogr B Anal Technol Biomed Life Sci. 2005;817(2):193–7.
59. Kim YG, Kim HJ, Kwon JW, Kim WB, Lee MG. Bioequivalence of clarithromycin tablet formulations assessed in Korean males. Int J Clin Pharmacol Ther. 2001;39(8):356–61.
60. Koytchev R, Ozalp Y, Erenmemisoglu A, van der Meer MJ, Alpan RS. Studies on the bioequivalence of different strengths of tablets containing clarithromycin. Arzneimittelforschung. 2004;54(9A):588–93.
61. Burkhardt O, Borner K, Stass H, Beyer G, Allewelt M, Nord CE, et al. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clarithromycin, and concentrations in serum, saliva and faeces. Scand J Infect Dis. 2002;34(12):898–903.
62. Bahrami G, Mohammadi B. Determination of clarithromycin in human serum by high-performance liquid chromatography after pre-column derivatization with 9-fluorenylmethyl chloroformate: application to a bioequivalence study. J Chromatogr B Anal Technol Biomed Life Sci. 2007;850(1–2):417–22.
63. Nilsen OG, Aamo T, Zahlsen K, Svarva P. Macrolide pharmacokinetics and dose scheduling of roxithromycin. Diagn Microbiol Infect Dis. 1992;15(4 Suppl):71S–6S.
64. Khan MK, Khan MF, Mustafa G, Sualah M. Bioequivalence study of two oral formulations of clarithromycin in human male subjects. Pak J Pharm Sci. 2011;24(1):43–6.
65. Lohitnavy M, Lohitnavy O, Sareekan K, Chaiyaput W. Average bioequivalence study of clarithromycin tablets in healthy male volunteers. J Clin Pharm Ther. 2003;28(3):187–90.
66. Lohitnavy O, Lohitnavy M, Sareekan K, Polnok S, Taytiwat P. Average bioequivalence of generic clarithromycin tablets in healthy Thai male volunteers. Biopharm Drug Dispos. 2003;24(6):229–31.
67. Lohitnavy M, Lohitnavy O, Wittaya-areekul S, Sareekan K, Polnok S, Chaiyaput W. Average bioequivalence of clarithromycin immediate released tablet formulations in healthy male volunteers. Drug Dev Ind Pharm. 2003;29(6):653–9.
68. Lohitnavy M, Lohitnavy O, Chaijittiprasert K, Taytiwat P, Polnok S, Sareekan K. Pharmacokinetic and bioequivalence studies of generic clarithromycin tablets in healthy male volunteers. Pharmazie. 2003;58(1):72–3.
69. Zhou Q, Ruan Z, Yuan H, Jiang B, Xu D. RP-HPLC analysis of flucloxacillin in human plasma: validation and application to a bioequivalence study. Pharmazie. 2007;62(2):101–4.
70. Paton DM, Mander P, Avery RJ. Bioavailability and half-life of two preparations of flucloxacillin. N Z Med J. 1982;95(719):766–8.
71. Drusano GL, Standiford HC, Plaisance K, Forrest A, Leslie J, Caldwell J. Absolute oral bioavailability of ciprofloxacin. Antimicrob Agents Chemother. 1986;30(3):444–6.
72. Mather LE, Austin KL, Philpot CR, McDonald PJ. Absorption and bioavailability of oral erythromycin. Br J Clin Pharmacol. 1981;12(2):131–40.
73. Rodriguezibanez M. Transintestinal secretion of ciprofloxacin, grepafloxacin and sparfloxacin: in vitro and in situ inhibition studies. Eur J Pharm Biopharm. 2003;55(2):241–6.
74. Merino V, Freixas J, del Val Bermejo M, Garrigues TM, Moreno J, Pla-Delfina JM. Biophysical models as an approach to study passive absorption in drug development: 6-fluoroquinolones. J Pharm Sci. 1995;84(6):777–82.
75. Nakanishi T, Tamai I. Genetic polymorphisms of OATP transporters and their impact on intestinal absorption and hepatic disposition of drugs. Drug Metab Pharmacokinet. 2012;27(1):106–21.
76. Teh LK, Lee WL, Amir J, Salleh MZ, Ismail R. Single step PCR for detection of allelic variation of MDR1 gene (P-glycoprotein) among three ethnic groups in Malaysia. J Clin Pharm Ther. 2007;32(3):313–9.
77. Westphal JF, Deslandes A, Brogard JM, Carbon C. Reappraisal of amoxycillin absorption kinetics. J Antimicrob Chemother. 1991;27(5):647–54.
78. Arakawa H, Shirasaka Y, Haga M, Nakanishi T, Tamai I. Active intestinal absorption of fluoroquinolone antibacterial agent ciprofloxacin by organic anion transporting polypeptide, Oatp1a5. Biopharm Drug Dispos. 2012;33(6):332–41.
79. Brillault J, De Castro WV, Couet W. Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model. Antimicrob Agents Chemother. 2010;54(1):543–5.
80. Sinko PJ, Amidon GL. Characterization of the oral absorption of beta-lactam antibiotics. I. Cephalosporins: determination of intrinsic membrane absorption parameters in the rat intestine in situ. Pharm Res. 1988;5(10):645–50.
81. Garver E, Hugger ED, Shearn SP, Rao A, Dawson PA, Davis CB, et al. Involvement of intestinal uptake transporters in the absorption of azithromycin and clarithromycin in the rat. Drug Metab Dispos. 2008;36(12):2492–8.
82. Chowbay B, Zhou S, Lee E. An interethnic comparison of polymorphisms of the genes encoding drug-metabolizing enzymes and drug transporters: experience in Singapore. Drug Metab Rev. 2005;37(2):327–78.
83. Saito H, Fukasawa Y, Otsubo Y, Yamada K, Sezaki H, Yamashita S. Carrier-mediated transport of macrolide antimicrobial agents across Caco-2 cell monolayers. Pharm Res. 2000;17(6):761–5.
84. Johnson JA, Livingston TN. Differences between blacks and whites in plasma protein binding of drugs. Eur J Clin Pharmacol. 1997;51(6):485–8.
85. Zhu Z, Wang AX, Li Y. Clinical pharmacokinetics and therapeutic efficacy of ceftriaxone in Chinese adults. Chemotherapy. 1997;43(3):218–26.
86. Norrby SR. Carbapenems. Med Clin North Am. 1995;79(4):745–59.
87. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother. 2001;45(6):1843–6.
88. Bergan T, Engeset A, Olszewski W. Does serum protein binding inhibit tissue penetration of antibiotics? Rev Infect Dis. 1987;9(4):713–8.
89. Muto C, Liu P, Chiba K, Suwa T. Pharmacokinetic–pharmacodynamic analysis of azithromycin extended release in Japanese patients with common respiratory tract infectious disease. J Antimicrob Chemother. 2011;66(1):165–74.
90. Son DS, Osabe M, Shimoda M, Kokue E. Contribution of alpha 1-acid glycoprotein to species difference in lincosamides-plasma protein binding kinetics. J Vet Pharmacol Ther. 1998;21(1):34–40.
91. Prandota J, Tillement JP, d’Athis P, Campos H, Barre J. Binding of erythromycin base to human plasma proteins. J Int Med Res. 1980;8(Suppl 2):1–8.
92. Flaherty JF Jr, Gatti G, White J, Bubp J, Borin M, Gambertoglio JG. Protein binding of clindamycin in sera of patients with AIDS. Antimicrob Agents Chemother. 1996;40(5):1134–8.
93. Lebel M. Pharmacokinetic properties of clarithromycin: a comparison with erythromycin and azithromycin. Can J Infect Dis. 1993;4(3):148–52.
94. Zhou QT, He B, Zhang C, Zhai SD, Liu ZY, Zhang J. Pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study. Drugs Aging. 2011;28(11):903–12.
95. Ikawa K, Morikawa N, Ohge H, Ikeda K, Sueda T, Taniwaki M, et al. Pharmacokinetic–pharmacodynamic target attainment analysis of meropenem in Japanese adult patients. J Infect Chemother. 2010;16(1):25–32.
96. Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003;4(4):397–410.
97. Yamada S, Tang M, Richardson K, Halaschek-Wiener J, Chan M, Cook VJ, et al. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population. Pharmacogenomics. 2009;10(9):1433–45.
98. Oparaoji EC, Siram S, Elemihe U, Mezghebe HM, Cho T, Bashiri M, et al. Aminoglycoside pharmacokinetics in African-Americans with normal renal function. J Clin Pharm Ther. 1998;23(3):191–7.
99. Maki N, Ohkuchi A, Tashiro Y, Kim MR, Le M, Sakamoto T, et al. Initial dose of vancomycin based on body weight and creatinine clearance to minimize inadequate trough levels in Japanese adults. Eur J Clin Microbiol Infect Dis. 2012;31(10):2537–43.
100. Sugie M, Asakura E, Zhao YL, Torita S, Nadai M, Baba K, et al. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother. 2004;48(3):809–14.
101. Griffiths NM, Hirst BH, Simmons NL. Active intestinal secretion of the fluoroquinolone antibacterials ciprofloxacin, norfloxacin and pefloxacin; a common secretory pathway? J Pharmacol Exp Ther. 1994;269(2):496–502.
102. Ito T, Yano I, Tanaka K, Inui KI. Transport of quinolone antibacterial drugs by human P-glycoprotein expressed in a kidney epithelial cell line, LLC-PK1. J Pharmacol Exp Ther. 1997;282(2):955–60.
103. Pan WH, Yeh WT, Weng LC. Epidemiology of metabolic syndrome in Asia. Asia Pac J Clin Nutr. 2008;17(Suppl 1):37–42.
104. Wulan SN, Westerterp KR, Plasqui G. Ethnic differences in body composition and the associated metabolic profile: a comparative study between Asians and Caucasians. Maturitas. 2010;65(4):315–9.
105. Deurenberg P, Deurenberg-Yap M, Guricci S. Asians are different from Caucasians and from each other in their body mass index/body fat per cent relationship. Obes Rev. 2002;3(3):141–6.
106. Liska D, Dufour S, Zern TL, Taksali S, Cali AM, Dziura J, et al. Interethnic differences in muscle, liver and abdominal fat partitioning in obese adolescents. PLoS One. 2007;2(6):e569.
107. McLeay SC, Morrish GA, Kirkpatrick CM, Green B. The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet. 2012;51(5):319–30.
108. Walpole SC, Prieto-Merino D, Edwards P, Cleland J, Stevens G, Roberts I. The weight of nations: an estimation of adult human biomass. BMC Public Health. 2012;12:439.
109. Abe T, Bemben MG, Kondo M, Kawakami Y, Fukunaga T. Comparison of skeletal muscle mass to fat-free mass ratios among different ethnic groups. J Nutr Health Aging. 2012;16(6):534–8.
110. Hruschka DJ, Rush EC, Brewis AA. Population differences in the relationship between height, weight, and adiposity: an application of Burton’s model. Am J Phys Anthropol. 2013;151(1):68–76.
111. Rush EC, Freitas I, Plank LD. Body size, body composition and fat distribution: comparative analysis of European, Maori, Pacific Island and Asian Indian adults. Br J Nutr. 2009;102(4):632–41.
112. Deurenberg P, Yap M, van Staveren WA. Body mass index and percent body fat: a meta analysis among different ethnic groups. Int J Obes Relat Metab Disord. 1998;22(12):1164–71.
113. Roberts DF. Body weight, race and climate. Am J Phys Anthropol. 1953;11(4):533–58.
114. Piers LS, Rowley KG, Soares MJ, O’Dea K. Relation of adiposity and body fat distribution to body mass index in Australians of Aboriginal and European ancestry. Eur J Clin Nutr. 2003;57(8):956–63.
115. Zhou SF, Liu JP, Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009;41(2):89–295.
116. Lou YC. Differences in drug metabolism polymorphism between Orientals and Caucasians. Drug Metab Rev. 1990;22(5):451–75.
117. McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012;8(3):371–82.
118. Ahsan CH, Renwick AG, Waller DG, Challenor VF, George CF, Amanullah M. The influence of dose and ethnic origins on the pharmacokinetics of nifedipine. Clin Pharmacol Ther. 1993;54(3):329–38.
119. Zuo LJ, Guo T, Xia DY, Jia LH. Allele and genotype frequencies of CYP3A4, CYP2C19, and CYP2D6 in Han, Uighur, Hui, and Mongolian Chinese populations. Genet Test Mol Biomarkers. 2012;16(2):102–8.
120. Maeda K, Ikeda Y, Fujita T, Yoshida K, Azuma Y, Haruyama Y, et al. Identification of the rate-determining process in the hepatic clearance of atorvastatin in a clinical cassette microdosing study. Clin Pharmacol Ther. 2011;90(4):575–81.
121. Weber WW, Hein DW. N-acetylation pharmacogenetics. Pharmacol Rev. 1985;37(1):25–79.
122. Gumbo T, Louie A, Liu W, Brown D, Ambrose PG, Bhavnani SM, et al. Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations. Antimicrob Agents Chemother. 2007;51(7):2329–36.
123. Horai Y, Ishizaki T. N-acetylation polymorphism of dapsone in a Japanese population. Br J Clin Pharmacol. 1988;25(4):487–94.
124. Bressolle F, Gouby A, Martinez JM, Joubert P, Saissi G, Guillaud R, et al. Population pharmacokinetics of amikacin in critically ill patients. Antimicrob Agents Chemother. 1996;40(7):1682–9.
125. Yin OQ, Tomlinson B, Chow MS. Variability in renal clearance of substrates for renal transporters in Chinese subjects. J Clin Pharmacol. 2006;46(2):157–63.
126. Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. Eur J Pharm Sci. 2006;27(5):425–46.
127. Vasu S, Adithan C, Shashindran CH, Asad M, Koumaravelou K, Topno I. Effect of two types of Indian breakfast on bioavailability of cefuroxime axetil. Indian J Med Res. 2000;112:104–8.
128. Chen RR, Lee TY, Hsieh WC. Effect of food on pharmacokinetics of cefuroxime axetil in Chinese subjects. J Formos Med Assoc. 1992;91(12):1177–81.
129. Karim S, Ahmed T, Monif T, Saha N, Sharma PL. The effect of four different types of food on the bioavailability of cefaclor. Eur J Drug Metab Pharmacokinet. 2003;28(3):185–90.
130. Conney AH, Reidenberg MM. Cigarette smoking, coffee drinking, and ingestion of charcoal-broiled beef as potential modifiers of drug therapy and confounders of clinical trials. J Pharmacol Exp Ther. 2012;342(1):9–14.
131. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J. 2013;13(1):1–11.
132. Li XY, Gao F, Li ZQ, Guan W, Feng WL, Ge RL. Comparison of the pharmacokinetics of sulfamethoxazole in male Chinese volunteers at low altitude and acute exposure to high altitude versus subjects living chronically at high altitude: an open-label, controlled, prospective study. Clin Ther. 2009;31(11):2744–54.
133. Li X-Y, Liu Y-N, Wang X-J, Zhu J-B, Yuan M, Li Y-P, et al. Comparison of the pharmacokinetics of sulfamethoxazole in native Han and Tibetan male Chinese volunteers living at high altitude. Eur J Drug Metab Pharmacokinet. 2012;37(4):263–9.
134. Gwilt PR, Nahhas RR, Tracewell WG. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet. 1991;20(6):477–90.
135. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA. 2009;301(20):2129–40.
136. Harris MI. Noninsulin-dependent diabetes mellitus in black and white Americans. Diabetes Metab Rev. 1990;6(2):71–90.
137. Weinstein L, Meade RH. Absorption and excretion of penicillin injected into the muscles of patients with diabetes mellitus. Nature. 1961;192:987–8.
138. Lerner PI, Weinstein L. Abnormalities of absorption of benzylpenicillin G and sulfisoxazole in patients with diabetes mellitus. Am J Med Sci. 1964;248:37–51.
139. Fass RJ, Saslaw S. Clindamycin: clinical and laboratory evaluation of parenteral therapy. Am J Med Sci. 1972;263(5):368–82.
140. Maple-Brown LJ, Cunningham J, Hodge AM, Weeramanthri T, Dunbar T, Lawton PD, et al. High rates of albuminuria but not of low eGFR in urban indigenous Australians: the DRUID study. BMC Public Health. 2011;11:346.
141. Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 2013;34(1):45–78.
142. Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2006;45(10):957–64.
143. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997;62(3):248–60.
144. Kataoka M, Yokoyama T, Masaoka Y, Sakuma S, Yamashita S. Estimation of P-glycoprotein-mediated efflux in the oral absorption of P-gp substrate drugs from simultaneous analysis of drug dissolution and permeation. Eur J Pharm Sci. 2011;44(4):544–51.
145. Lagas JS, Sparidans RW, van Waterschoot RA, Wagenaar E, Beijnen JH, Schinkel AH. P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin. Antimicrob Agents Chemother. 2008;52(3):1034–9.
146. Ranaldi G, Islam K, Sambuy Y. Epithelial cells in culture as a model for the intestinal transport of antimicrobial agents. Antimicrob Agents Chemother. 1992;36(7):1374–81.
147. Hironaka T, Itokawa S, Ogawara K, Higaki K, Kimura T. Quantitative evaluation of PEPT1 contribution to oral absorption of cephalexin in rats. Pharm Res. 2009;26(1):40–50.
148. Morrison A, Levy R. Toward individualized pharmaceutical care of East Asians: the value of genetic testing for polymorphisms in drug-metabolizing genes. Pharmacogenomics. 2004;5(6):673–89.
149. Cropp CD, Yee SW, Giacomini KM. Genetic variation in drug transporters in ethnic populations. Clin Pharmacol Ther. 2008;84(3):412–6.
150. Sakurai A, Tamura A, Onishi Y, Ishikawa T. Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications. Expert Opin Pharmacother. 2005;6(14):2455–73.
151. Lin JH. Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol. 2007;3(1):81–92.
152. Togami K, Chono S, Morimoto K. Transport characteristics of clarithromycin, azithromycin and telithromycin, antibiotics applied for treatment of respiratory infections, in Calu-3 cell monolayers as model lung epithelial cells. Pharmazie. 2012;67(5):389–93.
153. Lau YY, Wu CY, Okochi H, Benet LZ. Ex situ inhibition of hepatic uptake and efflux significantly changes metabolism: hepatic enzyme-transporter interplay. J Pharmacol Exp Ther. 2004;308(3):1040–5.
154. Bendayan R. Renal drug transport: a review. Pharmacotherapy. 1996;16(6):971–85.
155. Morrish GA, Pai MP, Green B. The effects of obesity on drug pharmacokinetics in humans. Expert Opin Drug Metab Toxicol. 2011;7(6):697–706.
156. Grace E. Altered vancomycin pharmacokinetics in obese and morbidly obese patients: what we have learned over the past 30 years. J Antimicrob Chemother. 2012;67(6):1305–10.
157. Bergan T. Pharmacokinetics of tissue penetration of antibiotics. Rev Infect Dis. 1981;3(1):45–66.
158. Israili ZH, Dayton PG. Human alpha-1-glycoprotein and its interactions with drugs. Drug Metab Rev. 2001;33(2):161–235.
159. Routledge PA. The plasma protein binding of basic drugs. Br J Clin Pharmacol. 1986;22(5):499–506.
160. Huang Z, Ung T. Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics. Curr Drug Metab. 2013;14(2):226–38.
161. Kays MB, White RL, Gatti G, Gambertoglio JG. Ex vivo protein binding of clindamycin in sera with normal and elevated alpha 1-acid glycoprotein concentrations. Pharmacotherapy. 1992;12(1):50–5.
162. Son DS, Hariya S, Shimoda M, Kokue E. Contribution of alpha 1-acid glycoprotein to plasma protein binding of some basic antimicrobials in pigs. J Vet Pharmacol Ther. 1996;19(3):176–83.
163. Lee BL, Sachdeva M, Chambers HF. Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob Agents Chemother. 1991;35(12):2505–8.
164. Woo J, Cheung W, Chan R, Chan HS, Cheng A, Chan K. In vitro protein binding characteristics of isoniazid, rifampicin, and pyrazinamide to whole plasma, albumin, and alpha-1-acid glycoprotein. Clin Biochem. 1996;29(2):175–7.
165. Feely J, Grimm T. A comparison of drug protein binding and alpha 1-acid glycoprotein concentration in Chinese and Caucasians. Br J Clin Pharmacol. 1991;31(5):551–2.
166. Koh ET, Chi MS, Lowenstein FW. Comparison of selected blood components by race, sex, and age. Am J Clin Nutr. 1980;33(8):1828–35.
167. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med. 2009;37(3):840–51 (quiz 859).
168. Dulhunty JM, Roberts JA, Davis JS, Webb SA, Bellomo R, Gomersall C, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013;56(2):236–44.
169. Roberts JA, Lipman J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet. 2006;45(8):755–73.
170. Lorente L, Jimenez A, Martin MM, Iribarren JL, Jimenez JJ, Mora ML. Clinical cure of ventilator-associated pneumonia treated with piperacillin/tazobactam administered by continuous or intermittent infusion. Int J Antimicrob Agents. 2009;33(5):464–8.
171. Jang SB, Lee YJ, Park MS, Song YG, Kim JH, Kim HK, et al. Population pharmacokinetics of amikacin in a Korean clinical population. Int J Clin Pharmacol Ther. 2011;49(6):371–81.
172. Bernareggi A, Borghi A, Borgonovi M, Cavenaghi L, Ferrari P, Vekey K, et al. Teicoplanin metabolism in humans. Antimicrob Agents Chemother. 1992;36(8):1744–9.
173. Ogawa R, Kobayashi S, Sasaki Y, Makimura M, Echizen H. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection. Int J Clin Pharmacol Ther. 2013;51(5):357–66.
174. Yasuhara M, Iga T, Zenda H, Okumura K, Oguma T, Yano Y, et al. Population pharmacokinetics of vancomycin in Japanese adult patients. Ther Drug Monit. 1998;20(2):139–48.
175. Deng C, Liu T, Zhou T, Lu H, Cheng D, Zhong X, et al. Initial dosage regimens of vancomycin for Chinese adult patients based on population pharmacokinetic analysis. Int J Clin Pharmacol Ther. 2013;51(5):407–15.
176. Matthews SJ, Lancaster JW. Doripenem monohydrate, a broad-spectrum carbapenem antibiotic. Clin Ther. 2009;31(1):42–63.
177. Zhou HH, Chan YP, Arnold K, Sun M. Single-dose pharmacokinetics of ceftriaxone in healthy Chinese adults. Antimicrob Agents Chemother. 1985;27(2):192–6.
178. Flores-Murrieta FJ, Aguilar-Cota ME, Granados-Soto V, Medina-Santillan R, Reyes-Garcia G, Herrera JE. Oral pharmacokinetics of cefaclor in Mexican subjects. Proc West Pharmacol Soc. 2001;44:71–2.
179. Iida S, Kinoshita H, Kawanishi T, Hayashi M. The pharmacokinetics of ceftriaxone based on population pharmacokinetics and the prediction of efficacy in Japanese adults. Eur J Drug Metab Pharmacokinet. 2009;34(2):107–15.
180. Barbhaiya RH. A pharmacokinetic comparison of cefadroxil and cephalexin after administration of 250, 500 and 1000 mg solution doses. Biopharm Drug Dispos. 1996;17(4):319–30.
181. Liew KB, Peh KK, Loh GO, Tan YT. Three-ways crossover bioequivalence study of cephalexin in healthy Malay volunteers. Drug Dev Ind Pharm. 2014;40(9):1156–62.
182. Lode H, Stahlmann R, Koeppe P. Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000. Antimicrob Agents Chemother. 1979;16(1):1–6.
183. Ohkawa M, Hirano S, Tokunaga S, Motoi I, Shoda R, Ikeda A, et al. Pharmacokinetics of cefotetan in normal subjects and patients with impaired renal function. Antimicrob Agents Chemother. 1983;23(1):31–5.
184. Welling PG, Selen A, Pearson JG, Kwok F, Rogge MC, Ifan A, et al. A pharmacokinetic comparison of cephalexin and cefadroxil using HPLC assay procedures. Biopharm Drug Dispos. 1985;6(2):147–57.
185. Huang C, Gao J, Miao L. Simultaneous determination of flucloxacillin and ampicillin in human plasma by ultra performance liquid chromatography–tandem mass spectrometry and subsequent application to a clinical study in healthy Chinese volunteers. J Pharm Biomed Anal. 2012;59:157–61.
186. Hori R, Okumura K, Kamiya A, Nihira H, Nakano H. Ampicillin and cephalexin in renal insufficiency. Clin Pharmacol Ther. 1983;34(6):792–8.
187. C-h Xia, Y-q Xiong, G-j Wang. An improved high-performance liquid chromatographic method with a solid-phase extraction for the determination of piperacillin and tazobactam: application to pharmacokinetic study of different dosage in Chinese healthy volunteers. Biomed Chromatogr. 2007;21(7):680–6.
188. Raveendran R, Adithan C, Sriram G, Krishnan M, Bapna JS. Ampicillin pharmacokinetics in Indian geriatric subjects. Indian J Med Sci. 1990;44(3):61–4.
189. Guibert J, Kitzis MD, Yvelin C, Acar JF. Pharmacokinetics of single intravenous and intramuscular doses of cefotetan in normal human volunteers. J Antimicrob Chemother. 1983;11(Suppl):201–6.
190. Carver PL, Nightingale CH, Quintiliani R. Pharmacokinetics and pharmacodynamics of total and unbound cefoxitin and cefotetan in healthy volunteers. J Antimicrob Chemother. 1989;23(1):99–106.
191. Shi S, Liu Y, Li Z, Zheng H, Lv Y, Chen H. Pharmacokinetics and tolerability of intravenous cefotetan disodium for injection in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. Clin Ther. 2010;32(10):1832–41.
192. Bergan T. Extravascular penetration of ciprofloxacin. A review. Diagn Microbiol Infect Dis. 1990;13(2):103–14.
193. Lubasch A, Keller I, Borner K, Koeppe P, Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother. 2000;44(10):2600–3.
194. Mignot A, Guillaume M, Brault M, Gualano V, Millerioux L, Gohler K, et al. Multiple-dose pharmacokinetics and excretion balance of gatifloxacin, a new fluoroquinolone antibiotic, following oral administration to healthy Caucasian volunteers. Chemotherapy. 2002;48(3):116–21.
195. North DS, Fish DN, Redington JJ. Levofloxacin, a second-generation fluoroquinolone. Pharmacotherapy. 1998;18(5):915–35.
196. Xu YH, Li D, Liu XY, Li YZ, Lu J. High performance liquid chromatography assay with ultraviolet detection for moxifloxacin: validation and application to a pharmacokinetic study in Chinese volunteers. J Chromatogr B Anal Technol Biomed Life Sci. 2010;878(32):3437–41.
197. Kanjanawart S, Gaysonsiri D, Phunikom K, Simasathiansopon S, Tangsucharit P, Vannaprasaht S, et al. Comparative bioavailability of two moxifloxacin tablet products after single dose administration under fasting conditions in a balanced, randomized and cross-over study in healthy volunteers. Int J Clin Pharmacol Ther. 2013;51(3):249–54.
198. Wynalda MA, Hutzler JM, Koets MD, Podoll T, Wienkers LC. In vitro metabolism of clindamycin in human liver and intestinal microsomes. Drug Metab Dispos. 2003;31(7):878–87.
199. Flaherty JF, Rodondi LC, Guglielmo BJ, Fleishaker JC, Townsend RJ, Gambertoglio JG. Comparative pharmacokinetics and serum inhibitory activity of clindamycin in different dosing regimens. Antimicrob Agents Chemother. 1988;32(12):1825–9.
200. Martinez-Jimenez CP, Jover R, Donato MT, Castell JV, Gomez-Lechon MJ. Transcriptional regulation and expression of CYP3A4 in hepatocytes. Curr Drug Metab. 2007;8(2):185–94.
201. Mizushima Y, Hiratsuka H. General clinical study on Te-031 (A-56268). Chemotherapy. 1988;368(Suppl 3):452–99.
202. Sennello LT, Chu SY, Wilon DS. Single dose pharmacokinetics of Abbott-56268 (TE-031) after oral dosing. Program and abstracts of the twenty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 1986.
203. Yu MS, Qiu XF, Xue JG, Liu ZD, Tan JZ, Li HJ, et al. Mitochondrial DNA polymorphism in Chinese. Sci Sin B. 1988;31(7):860–72.
204. Leiro-Fernandez V, Valverde D, Vazquez-Gallardo R, Botana-Rial M, Constenla L, Agundez JA, et al. N-acetyltransferase 2 polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity in Caucasians. Int J Tuberc Lung Dis. 2011;15(10):1403–8.
205. Chamorro JG, Castagnino JP, Musella RM, Nogueras M, Aranda FM, Frias A, et al. Sex, ethnicity, and slow acetylator profile are the major causes of hepatotoxicity induced by antituberculosis drugs. J Gastroenterol Hepatol. 2013;28(2):323–8.
206. Ganiswarna SG, Wilmana PF, Setiabudy R, Ringoringo VS. Bioavailability of rifampicin caplets (600 mg and 450 mg) in healthy Indonesian subjects. Int J Clin Pharmacol Ther Toxicol. 1986;24(2):60–4.
207. Flores-Murrieta FJ, Castaneda-Hernandez G, Herrera JE, Hong E. Determination of oral rifampin pharmacokinetic parameters in Mexicans and comparison with other populations: absence of evidence for interethnic variability. Arch Med Res. 1994;25(4):381–5.
208. Buniva G, Pagani V, Carozzi A. Bioavailability of rifampicin capsules. Int J Clin Pharmacol Ther Toxicol. 1983;21(8):404–9.
209. Yamashita N, Matschke K, Gandhi A, Korth-Bradley J. Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects. J Clin Pharmacol. Epub 2013 Nov 18. doi:10.1002/jcph.236.
210. Liang SH, Sheng WH, Huang YT, Wu FL, Chang SC. Pharmacokinetics and safety of multiple intravenous doses of daptomycin in a Taiwanese adult population. Chemotherapy. 2009;55(2):91–6.
211. Mizuyachi K, Hara K, Wakamatsu A, Nohda S, Hirama T. Safety and pharmacokinetic evaluation of intravenous colistin methanesulfonate sodium in Japanese healthy male subjects. Curr Med Res Opin. 2011;27(12):2261–70.
212. Sasaki T, Takane H, Ogawa K, Isagawa S, Hirota T, Higuchi S, et al. Population pharmacokinetic and pharmacodynamic analysis of linezolid and a hematologic side effect, thrombocytopenia, in Japanese patients. Antimicrob Agents Chemother. 2011;55(5):1867–73.
213. Dehghanyar P, Burger C, Zeitlinger M, Islinger F, Kovar F, Muller M, et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother. 2005;49(6):2367–71.
214. Turnidge JD. The pharmacodynamics of beta-lactams. Clin Infect Dis. 1998;27(1):10–22.
215. Kremer JM, Wilting J, Janssen LH. Drug binding to human alpha-1-acid glycoprotein in health and disease. Pharmacol Rev. 1988;40(1):1–47.
216. Landersdorfer CB, Kirkpatrick CM, Kinzig-Schippers M, Bulitta JB, Holzgrabe U, Drusano GL, et al. Population pharmacokinetics at two dose levels and pharmacodynamic profiling of flucloxacillin. Antimicrob Agents Chemother. 2007;51(9):3290–7.
217. Thummel KE, Brimer C, Yasuda K, Thottassery J, Senn T, Lin Y, et al. Transcriptional control of intestinal cytochrome P-4503A by 1alpha,25-dihydroxy vitamin D3. Mol Pharmacol. 2001;60(6):1399–406.
218. Davey PG. The pharmacokinetics of clarithromycin and its 14-OH metabolite. J Hosp Infect. 1991;19(Suppl A):29–37.
219. Nauta EH, Mattie H. Pharmacokinetics of flucloxacillin and cloxacillin in healthy subjects and patients on chronic intermittent haemodialysis. Br J Clin Pharmacol. 1975;2(2):111–21.
220. Arancibia A, Guttmann J, Gonzalez G, Gonzalez C. Absorption and disposition kinetics of amoxicillin in normal human subjects. Antimicrob Agents Chemother. 1980;17(2):199–202.
221. Chien SC, Rogge MC, Gisclon LG, Curtin C, Wong F, Natarajan J, et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother. 1997;41(10):2256–60.
222. Welshman IR, Sisson TA, Jungbluth GL, Stalker DJ, Hopkins NK. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos. 2001;22(3):91–7.
223. Ballow C, Lettieri J, Agarwal V, Liu P, Stass H, Sullivan JT. Absolute bioavailability of moxifloxacin. Clin Ther. 1999;21(3):513–22.